Phase 1 Study of the Safety and Immunogenicity of Pfs230D1M-EPA/Alhydrogel and Pfs25M-EPA/Alhydrogel, a Transmission Blocking Vaccine Against Plasmodium Falciparum Malaria in Adults in the US and Mali
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 10 Oct 2017
At a glance
- Drugs Pfs25 Pfs230 malaria vaccine MVI (Primary) ; Hepatitis A-hepatitis B vaccine; Meningococcal vaccine groups A C Y W-135 conjugate
- Indications Malaria
- Focus Adverse reactions
- 04 Oct 2017 Planned End Date changed from 30 Sep 2017 to 30 Sep 2018.
- 23 Nov 2016 Planned End Date changed from 1 Dec 2017 to 1 Sep 2017.
- 03 Dec 2015 Planned primary completion date changed from 1 May 2017 to 1 Mar 2017 as reported by ClinicalTrials.gov record.